Researchers Highlight Hormone Therapy Type as Key to Memory Benefits After Menopause

What's Happening?

A study published in Neurology has found that the type of hormone therapy used post-menopause can significantly impact memory performance. The research, conducted by the Centre for Addiction and Mental Health in Toronto, analyzed data from 7,251 cognitively healthy women, revealing that transdermal estradiol-2 (E2) therapy was associated with better episodic memory, while oral E2 improved prospective memory. The study also noted that earlier menopause onset was linked to worse memory and executive function. The findings suggest that hormone therapy type may influence cognitive performance differently across various memory types, although the study's cohort primarily consisted of White individuals with higher incomes, limiting generalizability.

Why It's Important?

The study's findings are significant as they contribute to the ongoing debate about the cognitive benefits of menopausal hormone therapy (MHT). Understanding the impact of different hormone therapy types on memory can inform more tailored approaches to maintaining brain health after menopause. This research could lead to improved treatment strategies for postmenopausal women, potentially enhancing their quality of life. However, the study's limitations, including its focus on healthy women and lack of diversity, highlight the need for further research to understand the therapy's effects on different populations.

What's Next?

Further research is needed to explore how hormone therapy might influence cognition in women with poor health, those who underwent early or premature menopause, and women of different ethnicities. Additionally, studies should investigate the impact of hormone therapy dosage, duration, and timing on cognitive performance. These efforts could lead to more personalized and effective treatment options for postmenopausal women, addressing the gaps identified in the current study.